Full Press Release Details
DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that executive management will participate in three upcoming investor conferences as follows:
• The 26thAnnual B. Riley Securities Investor ConferenceDate: Wednesday, May 20, 2026Location: The Ritz-Carlton, Marina Del Rey, California
• The 23rdAnnual Craig-Hallum Institutional Investor ConferenceDate: Thursday, May 28, 2026Location: Depot Renaissance Hotel Minneapolis, Minnesota
• Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026 at 9:55-10:25AM ETLocation: New York, New YorkWebcast:Click Here
There are no presentations for the B. Riley Securities and Craig-Hallum conferences.
AboutEtonPharmaceuticalsEton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, DESMODA™, GALZIN®, HEMANGEOL®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800 and ZENEO®hydrocortisone autoinjector. For more information, please visit our website atwww.etonpharma.com.